Comparateur d'entreprises

À propos

Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.

Revenus

$52.8B

Signal d'écart de nouvelles

Signaux institutionnels

Modèles en cascade

Relations clés

À propos

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

Revenus

$42.6B

Signal d'écart de nouvelles

Signaux institutionnels

Modèles en cascade

Relations clés